New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
06:05 EDTENDPEndo Health downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Endo Health citing valuation.
News For ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ENDP news | >>
March 2, 2015
16:26 EDTENDPOn The Fly: Closing Wrap
Subscribe for More Information
12:13 EDTENDPOn The Fly: Midday Wrap
Subscribe for More Information
07:16 EDTENDPEndo to divest AMS men's and prostate health businesses to Boston Scientific
Endo International (ENDP) announced it has entered into a definitive agreement with Boston Scientific (BSX), under which Boston Scientific will acquire Endo's American Medical Systems' Men's and Prostate Health businesses for up to $1.65B, with $1.6B in cash payable at closing. Endo is also eligible to receive a potential milestone payment of $50M in cash conditioned on Boston Scientific achieving certain product revenue milestones in the Men's Health and Prostate Health businesses in 2016. In addition, Endo is currently evaluating strategic alternatives for the AMS Women's Health business. The transaction is expected to close in the third quarter of 2015, subject to customary conditions, including the expiration or termination of any applicable waiting periods under applicable competition laws. Endo will classify and report results of AMS as Discontinued Operations. FY15 Endo guidance will be provided on a continuing operations basis.
07:15 EDTENDPEndo sees FY15 adjusted EPS ex-AMS $4.35-$4.55, consensus $4.88
Subscribe for More Information
07:11 EDTENDPEndo reports Q4 adjusted EPS $1.16, consensus $1.12
Reports Q4 revenue $799.96M, consensus $780.44M.
07:10 EDTENDPEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Boston Scientific (BSX) announced that it has entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems' urology portfolio, which includes the Men's Health and Prostate Health businesses, for $1.6B in up-front cash and a potential additional $50M milestone based on 2016 sales. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions. Upon completion of the transaction, the AMS Men's Health and Prostate Health businesses will become part of Boston Scientific Urology and Women's Health. The acquisition encompasses the AMS product portfolio for treating urologic conditions, including benign prostatic hyperplasia, male stress urinary incontinence and erectile dysfunction. These technologies complement Boston Scientific's strong kidney stone, pelvic organ prolapse, female stress urinary incontinence and abnormal uterine bleeding treatment portfolios, and together, will provide customers with a comprehensive urology, urogynecology and gynecologic surgery portfolio. The AMS women's health business for treating pelvic organ prolapse and female stress urinary incontinence is not included in the transaction. The AMS Men's Health and Prostate Health businesses generated 2014 sales of approximately $400M and adjusted operating income of approximately $130M, excluding amortization and certain allocated expenses. GAAP operating income, including amortization and certain allocated expenses, was approximately $60M in 2014. The acquisition is expected to result in annual pre-tax synergies in excess of $50M by the end of 2018. On an adjusted basis, the transaction is expected to be breakeven to adjusted earnings per share in 2015, accretive by at least 3c in 2016, approximately 7c in 2017, and increasingly accretive thereafter. The transaction is expected to be less accretive, or dilutive, as the case may be, on a GAAP basis 2015 through 2017, due to amortization expense and transaction and integration costs. The acquisition is being structured as an asset purchase for tax purposes. Boston Scientific intends to finance the acquisition through a combination of existing and newly committed credit facilities.
07:08 EDTENDPEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Subscribe for More Information
07:08 EDTENDPBoston Scientific enters $1.65B agreement with Endo to acquire urology portfolio
Subscribe for More Information
February 26, 2015
07:33 EDTENDPQLT Inc. reports Q4 EPS 31c, consensus 14c
Subscribe for More Information
February 24, 2015
14:31 EDTENDPBoston Scientific deal for Endo unit would be favorably received, says Needham
Subscribe for More Information
12:40 EDTENDPBoston Scientific may strike deal for Endo AMS unit within weeks, Reuters says
Boston Scientific (BSX) is reportedly close to buying Endo International's (ENDP) AMS medical device unit which could be valued at roughly $2B, reports Reuters, citing people familiar with the matter. The sources said the companies want to finalize a deal "within a matter of weeks" but cautioned that talks are continuing and could still fail. Reference Link
12:14 EDTENDPEndo near deal to sell AMS device unit to Boston Scientific, Reuters says
February 23, 2015
12:53 EDTENDPAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
09:02 EDTENDPAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTENDPEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 22, 2015
15:59 EDTENDPValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
09:17 EDTENDPEndo price target raised to $101 from $86 at Goldman
Subscribe for More Information
08:21 EDTENDPSummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.
February 19, 2015
16:34 EDTENDPAmerican Medical Systems enrolls 1,000th patient in PROPPER registry
American Medical Systems, or AMS, a subsidiary of Endo International, announced the enrollment of the 1,000th patient in the largest prospective, multi-year, global registry study of penile prosthetic outcomes in the world. The study, entitled PROPPER, or Prospective Registry of Outcomes with Penile Prosthesis for Erectile Restoration, is sponsored by AMS and is being conducted by a team of experienced urologists at 11 North American sites. It aims to better characterize real-world patient satisfaction and other outcomes among men who are receiving prosthetic implants to treat their erectile dysfunction. All patients enrolled in the registry will be implanted with penile implants manufactured by AMS, the majority of whom will receive the three piece inflatable penile prosthesis, the AMS 700.
06:13 EDTENDPEndo resumed with a Buy at Citigroup
Price target raised to $98 from $87.
1 | 2 | all recent ENDP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use